2.50p+0.25 (+11.11%)27 Jun 2025, 09:33
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Genincode PLC Fundamentals

Company NameGenincode PLCLast Updated2025-06-27
IndustryDiagnostics & ResearchSectorHealthcare
Shares in Issue286.882 mMarket Cap£7.17 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-£0.03EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0879Debt Equity Ratio0.1304
Asset Equity Ratio2.3629Cash Equity Ratio1.0337
Quick Ratio1.2890Current Ratio1.53
Price To Book Value5.7274ROCE0

Genincode PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Genincode PLC Company Financials

Assets202420232022
Tangible Assets£441,000.00£707,000.00£1.00 m
Intangible Assets£118,000.00£287,000.00£310,000.00
Investments000
Total Fixed Assets£559,000.00£994,000.00£1.31 m
Stocks£126,000.00£84,000.00£20,000.00
Debtors£610,000.00£509,000.00£614,000.00
Cash & Equivalents£1.17 m£2.53 m£9.75 m
Other Assets000
Total Assets£2.66 m£4.19 m£11.80 m
Liabilities202420232022
Creditors within 1 year£1.38 m£2.47 m£2.18 m
Creditors after 1 year£159,000.00£424,000.00£1.72 m
Other Liabilities000
Total Liabilities£1.54 m£2.90 m£3.90 m
Net assets£1.13 m£1.29 m£7.90 m
Equity202420232022
Called up share capital£1.77 m£958,000.00£958,000.00
Share Premium£18.48 m£15.55 m£15.55 m
Profit / Loss-£5.08 m-£7.02 m-£5.75 m
Other Equity£1.13 m£1.29 m£7.90 m
Preference & Minorities000
Total Capital Employed£1.13 m£1.29 m£7.90 m
Ratios202420232022
Debt Ratio£0.12£0.15£0.03
Debt-to-Equity£0.13£0.17£0.04
Assets / Equity2.36292.36292.3629
Cash / Equity1.03371.03371.0337
EPS-£0.03-£0.07-£0.06
Cash Flow202420232022
Cash from operating activities-£5.17 m-£7.51 m-£3.73 m
Cashflow before financing-£1.53 m-£7.60 m-£3.77 m
Increase in Cash-£1.48 m-£7.46 m-£4.46 m
Income202420232022
Turnover£2.70 m£2.16 m£1.43 m
Cost of sales£1.27 m£1.14 m£798,000.00
Gross Profit£1.43 m£1.02 m£632,000.00
Operating Profit-£5.13 m-£7.15 m-£5.90 m
Pre-Tax profit-£5.08 m-£7.02 m-£5.75 m

Genincode PLC Company Background

SectorHealthcare
ActivitiesGENinCode PLC is engaged in the genetic risk assessment, prediction, and prevention of cardiovascular diseases including coronary artery diseases such as angina and myocardial infarction (heart attack), stroke, heart failure, hypertension,and other vascular heart diseases. The company's current product portfolio comprises Cardio inCode, LiPID inCode, SuDD inCode, and Thrombo inCode. The company has only one reportable segment the sale of kits and the provision of support services. The Geographic Markets of the group are Chile, France, Italy, Sweden, Mexico, Spain, and the United Kingdom.
Latest Interim Date25 Sep 2024
Latest Fiscal Year End Date4 Jun 2025

Genincode PLC Directors

AppointedNamePosition
2025-03-26Mr. Paul Andrew Peter FoulgerExecutive Director,Chief Financial Officer and Company Secretary
2021-11-29Mr. David Eric EvansNon-Executive Director
2025-03-26Mr. Matthew Heaton WallsExecutive Director,Chief Executive Officer
2025-03-26Mr. William E. Rhodes IIINon-Executive Director,Chairman
2025-03-26Mr. Jordi Puig GilberteExecutive Director,Founder and Chief Operations Officer
2025-03-26Mr. Sergio Olivero RigauNon-Executive Director
2025-03-26Professor Huon Gray CBENon-Executive Director
2025-03-26Mr. Felix Wilhelm FruehNon-Executive Director

Genincode PLC Contact Details

Company NameGENinCode PLC
AddressOne St. Peters Square, Manchester, M2 3DE
Telephone+44 1865955847
Websitehttps://www.genincode.com

Genincode PLC Advisors